Lay Line Genomics S.p.a.

Abbvie Inc.

Gabriele Ugolini

Flaminia Pavone

Sara Marinelli

Antonino Cattaneo

Antonio Cattaneo

Sara Martinelli

Use of an anti-NGF antibody capable of inhibiting the binding between NGF and TrkA, capable of blocking the biological activity of TrkA for the preparation of a medicament for treating and/or preventing chronic pain.

Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect

According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.

Method for the potentiation of opioid analgesics effects on pain

Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.

Growing community of inventors

Rome, Italy

Gabriele Ugolini